Healio Reporting

September 19, 2021
1 min read

7 important updates for Childhood Cancer Awareness Month


Healio Reporting

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

September is Childhood Cancer Awareness Month.

The campaign is intended to spotlight the types of cancer that largely affect children, draw attention to survivorship issues, and raise funds for research and family support.

Source: Adobe Stock.

In conjunction with this observance, Healio presents the following updates in pediatric oncology that may be important to your practice.

  1. Age and ethnic background appeared associated with inadequate follow-up care among young adult childhood cancer survivors. Read more.
  2. RadFlix, a form of “distraction therapy”, allows children to watch movies or TV shows while they undergo radiation therapy. Read more.
  3. Young children with brain tumors experienced cognitive difficulties prior to adjuvant treatment, with those of a younger age at diagnosis and lower socioeconomic status at greatest risk. Read more.
  4. Genetic alterations of ALK, including clonal mutations and amplifications, in high-risk neuroblastoma demonstrated utility as independent predictors of poorer survival. Read more.
  5. Healio spoke with oncologists, endocrinologists and otolaryngologists about the potential drivers of this growing incidence of pediatric thyroid cancer, whether thyroid cancers are being overdiagnosed among children, and how future research aims to further characterize pediatric thyroid cancers as distinct from those occurring among adults. Read more.
  6. Children’s Hospital of Philadelphia has retained its distinction as the No. 1 children’s hospital for cancer in the country. The institution tops U.S. News & World Report’s list of best hospitals for pediatric cancer for 2021-2022. Read more.
  7. The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and effective among children and adolescents with high-risk classical Hodgkin lymphoma. Read more.